INTERACTION OF STEROID HORMONES AND HORMONE-SPECIFIC AUTOANTIBODIES IN THE REGULATION OF TUMOR PROLIFERATIVE ACTIVITY IN BREAST CANCER PATIENTS



Cite item

Full Text

Abstract

Abstract

Early it was shown that steroid hormones, estradiol and progesterone (E2 и Pg); antibodies of A and G class against benzo[a]pyrene (IgA1-Bp and IgG1-Bp), estradiol (IgA1-E2 and IgG1-E2), progesterone (IgA1-Pg and IgG1-Pg) and corresponding antiidiotypic antibodies (IgG2-E2 and IgG2-Pg) influenced on breast carcinogenesis. It was proposed that some of these effects way be enriched or inhibited at the simultaneous action of all these factors in breast cancer patients (BCP). So only some of these hormones and autoantibodies may be shown the significance associations with tumor growth. Our study aimed for research the participation of E2 и Pg, IgA1-Bp and IgG1-Bp, IgA1-E2 and IgG1-E2, IgA1-Pg and IgG1-Pg, IgG2-E2 and IgG2-Pg in regulation of tumor proliferation in BCP. Blood serum autoantibodies in 1258 BCP (620 with I stage and 638 with II–IV stages) were studied using ELISA technique. Steroid hormones concentrations were measured using “ImmunoEA-Estradiol”, and “ImmunoEA-Pg” (“Immunotech”, Russia). Tumor Ki67 was determined by standard immunohistochemical technique. Statistical analysis of the results was performed using CART algorithm of Statistica13.0 Software. The levels of Ki67 positive cells in tumors of I stage BCP were high when blood serum Pg concentrations were high and depended on levels of IgA1-Bp, IgG1-Bp, IgA1-E2 and IgG2-E2. The levels of Ki67 positive cells in tumors of II–IV stages BCP were high when IgG2-Pg were low and IgA1-Bp were high. The levels of these factors were the same in the blood serum of I stage and II–IV stages BCP. So the revealed difference in associations of tumor proliferation with studied serum factors were depended on changes of tumor cells receptivity during cancer progression. Immunoanalysis of IgG2-Pg and IgA1-Bp may be used for determine of tumor proliferation in BCP. It is advisable to research the antiproliferative properties of manufactured antibodies against Pg receptor for replenishment of IgG2-Pg deficit in BCP.

About the authors

Andrey N. Glushkov

Federal Research Center of Coal and Coal chemistry SB RAS, Institute of Human Ecology, Kemerovo, Russian Federation

Email: glushkovan@ihe.sbras.ru
ORCID iD: 0000-0002-8560-6719
SPIN-code: 9536-8530
Scopus Author ID: 7006323832
ResearcherId: Q-5985-2016

PhD, MD (Medicine), Professor, Chief Research Associate, Immunogenetics Laboratory, Institute of Human Ecology

Russian Federation, Kemerovo

Elena G. Polenok

Federal Research Center of Coal and Coal chemistry SB RAS, Institute of Human Ecology, Kemerovo, Russian Federation

Email: egpolenok@mail.ru
ORCID iD: 0000-0002-9368-2340
SPIN-code: 3925-0185
Scopus Author ID: 6506567994
ResearcherId: Q-5381-2016

PhD (Pharmacy), Leading Researcher Associate, Immunochemistry Laboratory, Institute of Human Ecology

Russian Federation, Kemerovo

Lyudmila A. Gordeeva

Federal Research Center of Coal and Coal chemistry SB RAS, Institute of Human Ecology, Kemerovo, Russian Federation

Email: gorsib@rambler.ru
ORCID iD: 0000-0001-5870-7584
SPIN-code: 6662-4616
Scopus Author ID: 14052058500

PhD (Biology), Leading Researcher Associate, Immunogenetics Laboratory, Institute of Human Ecology

Russian Federation, Kemerovo

Stella M. Mun

Federal Research Center of Coal and Coal chemistry SB RAS, Institute of Human Ecology, Kemerovo, Russian Federation

Email: stellamun@yandex.ru
ORCID iD: 0000-0002-5530-3469
SPIN-code: 5579-8939
Scopus Author ID: 7101645456
ResearcherId: J-6484-2018

PhD (Medicine), Senior Research Associate, Laboratory of Immunogenetics, Institute of Human Ecology

Russian Federation, Kemerovo

Artem E. Studennikov

Federal Research Center of Coal and Coal chemistry SB RAS, Institute of Human Ecology, Kemerovo, Russian Federation

Email: StudennikovAE@ihe.sbras.ru
ORCID iD: 0000-0002-6623-8818

PhD (Medicine), Senior Research Associate, Immunogenetics Laboratory, Institute of Human Ecology

Russian Federation, Kemerovo

Alexey M. Eliseikin

Federal Research Center of Coal and Coal chemistry SB RAS, Institute of Human Ecology, Kemerovo, Russian Federation

Email: aleksejelisejkin.98@bk.ru
SPIN-code: 8293-6721

Leading Biological Engineer, Biotechnology Laboratory, Institute of Human Ecology

Russian Federation, Kemerovo

Mikhail V. Kostyanko

Kemerovo State University, Institute of Fundamental Sciences, Kemerovo, Russian Federation

Email: kmvksu@mail.ru
ORCID iD: 0000-0003-0053-1752
SPIN-code: 5953-6554
Scopus Author ID: 6507008191

Leading Engineer, Department of Fundamental and Applied Chemistry, Institute of Fundamental Sciences

Russian Federation, Kemerovo

Vadim N. Zakharov

Kuzbass Clinical Oncology Dispensary, Kemerovo, Russian Federation

Email: vadim-zaxarov2016@ya.ru
ORCID iD: 0009-0003-1731-1534

PhD (Medicine), Main Physician

Russian Federation, Kemerovo

Alexander V. Antonov

Kuzbass Clinical Oncology Dispensary, Kemerovo, Russian Federation

Email: al0412@mail.ru
ORCID iD: 0000-0003-0802-9759
Scopus Author ID: 57190130097

Chief, Breast Cancer Department

Russian Federation, Kemerovo

Pavel V. Bayramov

Kuzbass Clinical Oncology Dispensary, Kemerovo, Russian Federation

Email: bayramov_pavel82@mail.ru
ORCID iD: 0000-0002-4649-5892
Scopus Author ID: 58912387800

Main Physician, Pathologoanatomical Department

Russian Federation, Kemerovo

Natalia E. Verzhbitskaya

Kuzbass Clinical Oncology Dispensary, Kemerovo, Russian Federation

Email: verzhbitskaia@mail.ru
ORCID iD: 0000-0003-3860-825X
Scopus Author ID: 59410662300

PhD (Medicine), Pathologist 

Russian Federation, Kemerovo

Gleb I. Kolpinsky

Kemerovo State Medical University, Kemerovo, Russian Federation;
Kemerovo Clinical Diagnostic Сenter, Kemerovo, Russian Federation

Author for correspondence.
Email: Glebss@mail.ru
ORCID iD: 0000-0002-5526-2687
SPIN-code: 6894-6419
Scopus Author ID: 56677706300

PhD, MD (Medicine), Professor, Department of Radiology, Radiotherapy and Oncology; Main Physician

Russian Federation, Kemerovo

References

  1. Аутеншлюс А.И., Архипов С.А., Михайлова Е.С., Архипова В.В., Вараксин Н.А. Сопряженность цитокинового профиля супернатанта инвазивной карциномы молочной железы с ее молекулярными и гистопатологическими характеристиками // Сибирский онкологический журнал, 2023 – Т. 22, №6. – С. 92-102. Autenshlyus A.I., Arkhipov S.A., Mikhaylova E.S., Arkhipova V.V., Varaksin N.A. Relationship between the cytokine profle of supernatants of invasive breast carcinoma and its molecular and histopathological characteristics. Sibirskij onkologičeskij žurnal = Siberian Journal of Oncology, 2023, Vol. 22, no. 6, pp. 92–102. (In Russ.) doi: 10.21294/1814-4861-2023-22-6-92-102
  2. Глушков А.Н. Клиническая иммунохимия канцерогенеза: новые задачи и перспективы. // Российский иммунологический журнал, 2013. – Т.7(16), №1. – С. 27-34. Glushkov A.N., The immunochemistry on carcinogenesis: the new tasks and perspectives. Rossiyskiy Immunologicheskiy Zhurnal = Russian Journal of Immunology, 2013. Vol. 7(16), no. 1, pp. 27-34. (In Russ.) https://elibrary.ru/download/elibrary_19023468_51971566.pdf
  3. Глушков А.Н., Поленок Е.Г., Гордеева Л.А., Байрамов П.В., Вержбицкая Н.Е., Антонов А.В., Колпинский Г.И., Костянко М.В. Антитела и анти-антитела, специфичные к эстрадиолу и прогестерону, и пролиферативная активность опухоли у больных раком молочной железы. // Сибирский онкологический журнал, 2024. – Т.23, №3. – С. 73-85. Glushkov A.N., Polenok E.G., Gordeeva L.A., Bayramov P.V., Verzhbitskaya N.E., Antonov A.V., Kolpinsky G.I., Kostyanko M.V. Antibodies and anti-antibodies specific to estradiol and progesterone and tumor proliferation in breast cancer patients. Sibirskij onkologičeskij žurnal = Siberian journal of oncology, 2024, Vol. 23, no. 3, pp. 73-85 (In Russ.) doi: 10.21294/1814-4861-2024-23-3-73-85
  4. Стрункин Д.Н., Конончук В.В., Гуляева Л.Ф., Богачев С.С., Проскурина А.С. Современные аспекты систематики, диагностики и лечения рака молочной железы. // Опухоли женской репродуктивной системы, 2022. – Т.18, №1. – С. 25-39. Strunkin D.N., Kononchuk V.V., Gulyaeva L.F., Bogachev S.S., Proskurina A.S. Current aspects of systematics, diagnosis and treatment of breast cancer. Opuholi ženskoj reproduktivnoj sistemy = Tumors of female reproductive system, 2022, Vol. 18, no. 1, pp. 25-39. (In Russ.) doi: 10.17650/1994-4098-2022-18-1-25-39
  5. Студеникина А.А., Михайлова Е.С., Архипов С.А., Вараксин Н.А., Проскура А.В., Аутеншлюс А.И. Биомаркеры крови и маркер пролиферации Ki-67 при раке молочной железы // Медицинская иммунология, 2023. – Т. 25, № 2. – С. 357-366. Studenikina A.A., Mikhaylova E.S., Arkhipov S.A., Varaksin N.A., Proskura A.V., Autenshlyus A.I. Blood biomarkers and Ki-67 proliferation marker in breast cancer. Meditsinskaya Immunologiya = Medical Immunology, 2023, Vol. 25, no. 2, pp. 357-366. (In Russ.) [doi: 110.15789/1563-0625-BBA-2570]
  6. Alluri P.G., Speers C., Chinnaiyan A.M. Estrogen receptor mutations and their role in breast cancer progression. Breast Cancer Res., 2014, Vol. 16, no. 6, pp. 494-502. doi: 10.1186/s13058-014-0494-7
  7. Bochskanl R., Thie M., Kirchner C.J. Active immunization of rabbits against progesterone: increase in hormone levels, and changes in metabolic clearance rates and in genital tract tissues. Steroid. Biochem., 1989, Vol.33, no. 3, pp. 349-355. doi: 10.1016/0022-4731(89)90323-3
  8. Borkowski A., Gyling M., Muquardt C., Body J.J., Leslercq G. Estrogen-like activity of a subpopulation of natural antiestrogen receptor autoantibodies in man. Endocrinology, 1991, Vol. 128, no.6, pp. 3283-3292. doi: 10.1210/endo-128-6-3283
  9. Caldwell B.V., Tillson S.A., Esber H., Thorneycroft I.H. Survival of tumors after immunization against oestrogens. Nature, 1971, Vol. 231, no. 5298, pp. 118-119. doi: 10.1038/231118a0
  10. Černohorská H., Klimešová S., Lepša L., Jinoch P., Milcová A., Schmuczerová J., Topinka J., Lábaj J. Influence of immunization with non-genotoxic PAH-KLH conjugates on the resistance of organisms exposed to benzo[a]pyrene. Mut. Res., 2012, Vol. 742, no. 1-2, pp. 2-10. doi: 10.1016/j.mrgentox.2011.10.016
  11. Chagnaud J.L., Faiderbe S., Geffard M. Identification and immunochemical characterization of IgA in sera of patients with mammary tumors. Int. J. Cancer., 1992, Vol. 50, no. 3, pp. 395-401. doi: 10.1002/ijc.2910500312
  12. Chaudhri R.A., Schwartz N., Elbaradie K., Schwartz Z., Boyan B.D. Role of ERα 36 in membrane-associated signaling by estrogen. Steroids, 2014, Vol. 81, pp. 74-80. doi: 10.1016/j.steroids.2013.10.020
  13. Chlebowski R.T., Rohan T.E., Manson J.E., Aragaki A.K., Kaunitz A., Stefanick M.L., Simon M.S., Johnson K.C., Wactawski-Wende J., O'Sullivan M.J., Adams-Campbell L.L., Nassir R., Lessin L.S., Prentice R.L. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials. JAMA Oncol.,2015, Vol. 1, no. 3, pp. 296-305. doi: 10.1001/jamaoncol.2015.0494
  14. De Buck S.S., Augustijns P., Muller C.P. Specific antibody modulates absorptive transport and metabolic activation of benzo[a]pyrene across Caco-2 monolayers. J. Pharmacol. Experim. Therap., 2005, Vol. 313, no. 2, pp. 640-646. doi: 10.1124/jpet.104.081034
  15. De Buck S.S., Augustijns P., Muller C.P. Specific antibody modulates absorptive transport and metabolic activation of benzo[a]pyrene across Caco-2 monolayers. J. Pharmacol. Experim. Therap., 2005, Vol. 313, no. 2, pp. 640-646. doi: 10.1124/jpet.104.081034
  16. De Buck S.S., Schellenberger M.T., Ensch C., Muller C.P. Effects of antibodies induced by a conjugate vaccine on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone absorptive transport, metabolism, and proliferation of human lung cells. Int. J. Cancer, 2010, Vol. 127, no. 3, pp. 513-520. doi: 10.1002/ijc.25073
  17. De Buck S.S., Schellenberger M.T., Ensch C., Muller C.P. Effects of antibodies induced by a conjugate vaccine on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone absorptive transport, metabolism, and proliferation of human lung cells. Int. J. Cancer, 2010, Vol. 127, no. 3, pp.513-520. doi: 10.1002/ijc.25073
  18. Elsaesser F. Effects of active immunization against oestradiol-17 beta, testosterone or progesterone on receptivity in the female rabbit and evaluation of specificity. J. Reprod. Fertil., 1980, Vol. 58, no.1, pp. 213-218. doi: 10.1530/jrf.0.0580213
  19. Fowler A.M., Salem K., DeGrave M., Ong I.M., Rassman S., Powers G.L., Kumar M., Michel C.J., Mahajan A.M. Progesterone Receptor Gene Variants in Metastatic Estrogen Receptor Positive Breast Cancer. Horm. Cancer, 2020, Vol. 11, no. 2, pp. 63-75. doi: 10.1007/s12672-020-00377-3
  20. Gammon M.D., Sagiv S.K., Eng S.M., Shantakumar S., Gaudet M.M., Teitelbaum S.L., Britton J.A., Terry M.B., Wang L.W., Wang Q., Stellman S.D., Beyea J., Hatch M., Kabat G.C., Wolff M.S., Levin B., Neugut A.I., Santella R.M. Polycyclic aromatic hydrocarbon-DNA adducts and breast cancer: a pooled analysis. Arch. Environ. Health, 2004, Vol. 59, no. 12, pp. 640-649. doi: 10.1080/00039890409602948
  21. Girdhar A., Raju K., Prasad K. Association between interleukin 6 immunohistochemical and plasma levels in invasive ductal carcinoma breast: a cross-sectional study. Biomed. Res. Ther., 2023, Vol. 10, no. 8, pp. 5843-5854. doi: 10.15419/bmrat.v10i8.826
  22. Glushkov A.N., Apalko S.V., Filipenko M.L., Matveeva V.A., Bakulina A.Yu., Lunin V.G., Kostyanko M.V. A Novel Approach to the Development of Anticarcinogenic Vaccines. Acta naturae, 2010, Vol. 2, no. 4(7), pp. 105-111. https://pubmed.ncbi.nlm.nih.gov/22649670/
  23. Glushkov A.N., Polenok E.G., Mun S.A., Gordeeva L.A. Immunization against environmental chemical carcinogens: pro and contra. Medical Hypotheses, 2019, Vol. 131, pp.109303. doi: 10.1016/j.mehy.2019.109303]
  24. Greiner M., Pfeiffer D., Smith R.D. Principles and practical application of the receiver operating characteristic analysis for diagnostic test. Prev. Vet. Med., 2000, Vol. 45, pp. 23–41. doi: 10.1016/S0167-5877(00)00115-X
  25. Grova N., Prodhomme E.J., Schellenberger M.T., Farinelle S., Muller C.P. Modulation of carcinogen bioavailability by immunisation with benzo[a]pyrene – conjugate vaccines. Vaccine, 2009, Vol. 27, no. 31, pp. 4142-4151. doi: 10.1016/j.vaccine.2009.04.052
  26. Harrod A., Lai C.F., Goldsbrough I., Simmons G.M., Oppermans N., Santos D.B., Győrffy B., Allsopp R.C., Toghill B.J., Balachandran K., Lawson M., Morrow C.J., Surakala M., Carnevalli L.S., Zhang P., Guttery D.S., Shaw J.A., Coombes R.C., Buluwela L., Ali S. Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer. Oncogene, 2022, Vol. 41, no.44, pp. 4905-4915. doi: 10.1038/s41388-022-02483-8.
  27. Hirose T., Morito K., Kizu R., Toriba A., Hayakawa K., Ogawa S., Inoue S., Muramatsu M., Masamune Y. Estrogenic/antiestrogenic activities of benzo[a]pyrene monohydroxy derivatives. J. Health Sci., 2001, Vol. 47, no. 6, pp. 552-558. doi: 10.1248/jhs.47.552
  28. Jerne N.K. Idiotypic networks and other preconceived ideas. Immunol. Rev., 1984, Vol. 79, pp. 5-24. doi: 10.1111/j.1600-065x.1984.tb00484.x
  29. Kang S.C., Lee B.M. Effect of estrogen receptor (ER) on benzo[a]pyrene-DNA adduct formation in human breast cancer cells. J. Toxicol. Environ. Health A., 2005, Vol. 68, no. 21, pp. 1833-1840. doi: 10.1080/15287390500182883
  30. Kong A.L., Pezzin L.E., Nattinger A.B. Identifying patterns of breast cancer care provided at high-volume hospitals: a classification and regression tree analysis. Breast Cancer Res. Treat., 2015, Vol. 153, no. 3, pp. 689-698. doi: 10.1007/s10549-015-3561-6
  31. Li Z, Wei H., Li S., Wu P., Mao X. The Role of Progesterone Receptors in Breast Cancer. Drug Des. Devel. Ther., 2022, Vol. 16, pp. 305-314. doi: 10.2147/DDDT.S336643
  32. Lin C.H., Zahid M., Kuo W.H., Hu F.C., Wang M.Y., Chen I.C., Beseler C.L., Mondal B., Lu Y.S., Rogan E.G., Cheng A.L. Estrogen-DNA Adducts and Breast Cancer Risk in Premenopausal Asian Women. Cancer Prev. Res. (Phila), 2023, Vol. 16, no. 3, pp. 153-161. doi: 10.1158/1940-6207.CAPR-22-0415
  33. Reding K.W., Han C.J., Whittington D., Zahid M., Rogan E.G., Langford D., Rohan T.E., Chlebowski R.T., Cheng T.D., Barrington W.E., Tinker L.F. Risk of Breast Cancer Associated with Estrogen DNA Adduct Biomarker. Cancer Epidemiol Biomarkers Prev., 2020, Vol. 29, no. 10, pp. 2096-2099. doi: 10.1158/1055-9965.EPI-20-0133
  34. Rosenberg M., Amir D., Folman Y. The effect of active immunization against progesterone on plasma concentrations of total and free progesterone, estradiol-17beta and LH in the cyclic ewe. Theriogenology, 1987, Vol. 28, no. 4, pp. 417-426. [doi: 10.1016/0093-691x(87)90246-9]
  35. Rundle A., Tang D., Hibshoosh H., Estabrook A., Schnabel F., Cao W., Grumet S., Perera F.P. The relationship between genetic damage from polycyclic aromatic hydrocarbons in breast tissue and breast cancer. Carcinogenesis, 2000, Vol. 21, no. 7, pp. 1281-1289. doi: 10.1093/carcin/21.7.1281
  36. Sagiv S.K., Gaudet M.M., Eng S.M., Abrahamson P.E., Shantakumar S., Teitelbaum S.L., Bell P., Thomas J.A., Neugut A.I., Santella R.M., Gammon M.D. Polycyclic aromatic hydrocarbon-DNA adducts and survival among women with breast cancer. Environ. Res., 2009, Vol. 109, no. 3, pp. 287-291. doi: 10.1016/j.envres.2008.11.005
  37. Sömjen D., Kohen F., Lieberherr M. Nongenomic effects of an anti-idiotypic antibody as an estrogen mimetic in female human and rat osteoblasts. J. Cell Biochem., 1997, Vol. 65, no.1, pp. 53-66. doi: 10.1002/(SICI)1097-4644(199704)65:1<53::AID-JCB6>3.0.CO;2-Y
  38. Spurgeon S.E., Hsieh Y.C., Rivadinera A., Beer T.M., Mori M., Garzotto M. Classification and regression tree analysis for the prediction of aggressive prostate cancer on biopsy. J. Urol., 2006, Vol. 175, no. 3 Pt 1, pp. 918-922. doi: 10.1016/S0022-5347(05)00353-8
  39. Tassignon J., Haeseleer F., Borkowski A. Natural antiestrogen receptor autoantibodies in man with estrogenic activity in mammary carcinoma cell culture: study of their mechanism of action; evidence for involvement of estrogen-like epitopes. J. Clin. Endocrinol. Metab., 1997, Vol. 82, no. 10, pp. 3464-3470. doi: 10.1210/jcem.82.10.4313
  40. Trabert B., Sherman M.E., Kannan N., Stanczyk F.Z. Progesterone and Breast Cancer. Endocr. Rev., 2020, Vol. 41, no. 2, pp. 320-44. doi: 10.1210/endrev/bnz001

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) Glushkov A.N., Polenok E.G., Gordeeva L.A., Mun S.M., Studennikov A.E., Eliseikin A.M., Kostyanko M.V., Zakharov V.N., Antonov A.V., Bayramov P.V., Verzhbitskaya N.E., Kolpinsky G.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies